Want to see ARQT full AI Analyst Report?

Arcutis Biotherapeutics (ARQT) Price & Analysis

994 Followers

ARQT Stock Chart & Stats

$25.14

$0.49(1.79%)

At close: Jul 27 4:00 PM EDT

$25.14

$0.49(1.79%)

Day’s Range― - ―

52-Week Range$19.30 - $33.30

Previous Close$28.11

Volume1.20M

Average Volume (3M)3.03M

Market Cap

$4.01B

Enterprise Value$3.44B

Total Cash (Recent Filing)$238.55M

Total Debt (Recent Filing)$114.14M

Price to Earnings (P/E)148.6

Beta0.70

Next Earnings

Oct 29, 2026

EPS Estimate

0.18

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.22

Shares Outstanding125,691,960

10 Day Avg. Volume2,179,706

30 Day Avg. Volume3,033,060

Financial Highlights & Ratios

PEG Ratio2.52

Price to Book (P/B)19.50

Price to Sales (P/S)9.82

P/FCF Ratio-585.47

Enterprise Value/Market Cap0.86

Enterprise Value/Revenue7.41

Enterprise Value/Gross Profit8.13

Enterprise Value/Ebitda79.18

Forecast

1Y Price Target

$39.83

Price Target Upside58.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)0.48

Revenue Forecast (FY)$538.56M

Bulls Say, Bears Say

Bulls Say

ZORYVE Commercial MomentumRapid ZORYVE prescription and revenue growth, together with higher full-year guidance, indicates expanding adoption across dermatology indications. Continued commercial execution and salesforce expansion could support durable top-line growth over the next several quarters.

Improving Cash GenerationPositive operating and free cash flow show that the recent earnings inflection is converting into cash rather than remaining purely accounting-based. This improves funding capacity for commercial expansion and pipeline investment while reducing reliance on external capital.

Strengthening ZORYVE ExclusivityA larger patent estate and long cited exclusivity timelines can protect ZORYVE from direct competition and support sustained product economics. This strengthens the commercial franchise while giving Arcutis time to expand indications, formulations, and patient adoption.

Bears Say

Persistent Gross-to-Net PressureHigh gross-to-net deductions limit the revenue retained from prescription growth and constrain margin expansion. If rebates, chargebacks, and access costs remain elevated, additional volume may translate into less incremental cash and earnings than headline sales suggest.

High Commercial Cost BaseThe expanding salesforce and related commercial investment are increasing operating costs faster than some expenses may scale. Although these investments can support growth, they also leave profitability more sensitive to prescription execution and sustained revenue expansion.

Pipeline Development RiskFuture growth beyond the current ZORYVE franchise depends partly on clinical programs that have not yet established efficacy or regulatory success. Negative or delayed readouts could narrow the development pipeline and reduce the potential for longer-term indication expansion.

Arcutis Biotherapeutics News

Arcutis Biotherapeutics price target raised to $44 from $38 at Guggenheim

Guggenheim raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $44 from $38 and keeps a Buy...

2d ago

ARQT

Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and $48 price...

6d ago

ARQT

Arcutis Biotherapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Steve Seedhouse initiated coverage of Arcutis Biotherapeutics (ARQT) with an Overweight rating and $48 price...

6d ago

ARQT

Arcutis Biotherapeutics presents data across Zoryve portfolio

Arcutis Biotherapeutics (ARQT) announced data presented across its Zoryve portfolio as well as real-world research on the long-term...

12d ago

ARQT

Arcutis Biotherapeutics partners with Simone Biles for new awareness campaign

Arcutis Biotherapeutics (ARQT) announced that World Champion gymnast Simone Biles has partnered with the company to launch its...

22d ago

ARQT

Arcutis Biotherapeutics falls -5.1%

Arcutis Biotherapeutics (ARQT) is down -5.1%, or -$1.33 to $24.81. Published first on TheFly – the ultimate source...

1M ago

ARQT

Arcutis Biotherapeutics rises 7.7%

Arcutis Biotherapeutics (ARQT) is up 7.7%, or $1.81 to $25.32. Published first on TheFly – the ultimate source...

1M ago

ARQT

S&P 600 adding ten companies at open on 9/21

Dow Jones Indices is making the following changes to the S&P 600 index effective prior to the open...

2M ago

EAT

Oruka Therapeutics appoints Todd Edwards as chief commercial officer

Oruka Therapeutics (ORKA) announced the appointment of Todd Edwards as chief commercial officer, effective August 24. Edwards joins...

2M ago

ARQT

ORKA

Arcutis-Backed Phase 3 ZORYVE Foam Study Targets Growth in Seborrheic Dermatitis

Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinical study. The phase 3 study “A Phase...

2M ago

ARQT

Arcutis says Health Canada approves Zoryve cream 0.05% for children with AD

Arcutis Canada announced that Health Canada has approved ZORYVE cream 0.05% for the topical treatment of mild to...

2M ago

ARQT

Arcutis Targets Real-World Itch Relief Data With New Phase 4 Roflumilast Study

Arcutis Biotherapeutics Inc ($ARQT) announced an update on their ongoing clinical study. Arcutis Backs New Itch Study in...

2M ago

ARQT

Arcutis Biotherapeutics Earnings Call Highlights Growth Momentum

Arcutis Biotherapeutics Inc (($ARQT)) has held its Q2 earnings call. Read on for the main highlights of the...

2M ago

ARQT

Arcutis (ARQT): Strong Zoryve Outperformance and Raised 2026 Sales Outlook Underscore Buy Rating

Analyst Tyler Van Buren of TD Cowen maintained a Buy rating on Arcutis Biotherapeutics, with a price target...

3M ago

ARQT

ARQT FAQ

What was Arcutis Biotherapeutics’s price range in the past 12 months?

Arcutis Biotherapeutics lowest stock price was $19.30 and its highest was $33.30 in the past 12 months.

What is Arcutis Biotherapeutics’s market cap?

Arcutis Biotherapeutics’s market cap is $4.01B.

When is Arcutis Biotherapeutics’s upcoming earnings report date?

Arcutis Biotherapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.

How were Arcutis Biotherapeutics’s earnings last quarter?

Arcutis Biotherapeutics released its earnings results on Aug 05, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.055 by $0.055.

Is Arcutis Biotherapeutics overvalued?

According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcutis Biotherapeutics pay dividends?

Arcutis Biotherapeutics does not currently pay dividends.

What is Arcutis Biotherapeutics’s EPS estimate?

Arcutis Biotherapeutics’s EPS estimate is 0.18.

How many shares outstanding does Arcutis Biotherapeutics have?

Arcutis Biotherapeutics has 125,691,960 shares outstanding.

What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?

Arcutis Biotherapeutics reported an EPS of $0.11 in its last earnings report, beating expectations of $0.055. Following the earnings report the stock price went down -2.472%.

Which hedge fund is a major shareholder of Arcutis Biotherapeutics?

Currently, no hedge funds are holding shares in ARQT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arcutis Biotherapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

15.05%

Trailing 12-Months

Asset Growth

38.62%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.

Arcutis Biotherapeutics (ARQT) Earnings & Revenues

Historic Earnings Reports

ARQT Company Deck

ARQT Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call communicated robust commercial momentum and multiple strategic wins — sizable revenue growth (+59% YoY), a return to quarterly profitability, raised full-year guidance, recent pediatric approval and an accepted sNDA — while simultaneously investing heavily in commercial expansion, patient access initiatives, and a broad pipeline. Near-term challenges include elevated SG&A from the salesforce build, gross-to-net still in the 50s with only moderate near-term improvement, early-stage readout risk on several programs, and some uncertainty around telehealth conversion dynamics. On balance, positive operational and financial momentum outweigh the manageable risks.View all ARQT earnings summaries

ARQT Stock 12 Month Forecast

Average Price Target

$39.83

▲(58.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"$18","49":"$49","25.75":"$25.8","33.5":"$33.5","41.25":"$41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$48.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.833333333333336,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$34.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,25.75,33.5,41.25,49],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,27.036923076923078,28.783846153846152,30.53076923076923,32.277692307692305,34.02461538461539,35.77153846153846,37.51846153846154,39.26538461538462,41.012307692307694,42.75923076923077,44.50615384615385,46.253076923076925,{"y":48,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,26.40871794871795,27.527435897435897,28.646153846153847,29.764871794871794,30.883589743589745,32.002307692307696,33.12102564102564,34.23974358974359,35.35846153846154,36.47717948717949,37.59589743589744,38.714615384615385,{"y":39.833333333333336,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.29,25.96,26.63,27.3,27.97,28.64,29.31,29.98,30.65,31.32,31.99,32.66,33.33,{"y":34,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.31,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.37,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.04,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.57,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.76,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.1,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.35,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.84,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.86,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.75,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.29,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >